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Innovative strategies are urgently needed for the treat-
ment of patients with malignant gliomas. Conventional
therapy consists primarily of surgical debulking and radi-
ation. Unfortunately, the median survival time for patients
after surgical intervention alone is 6 months, and only
7.5% of patients survive for 2 years. The addition of radi-
ation therapy can extend median survival to 9 months.2,3,14
Despite recent advances in drug delivery to tumors of the
CNS, little progress has been made in extending overall
patient survival. Consequently, efforts aimed at develop-
ing new therapies have focused on new treatment strat-
egies that specifically target tumor cells and spare normal
cells. One such modality, immunotherapy, has shown
promise in the spectrum of agents used against malignant
brain tumors. 
The identification and cloning of cytokines has provid-
ed one important tool for manipulation of the immunolog-
ical response to tumors. The generation of an effective
immune response requires both the presentation of a for-
eign antigen to lymphocytes and an appropriate stimulato-
ry molecule such as a cytokine. The rationale for using
cytokines is based on their ability to produce a strong local
inflammatory response that is specific to a particular cy-
tokine. High local concentrations closely mimic the natur-
al biology of cytokine action. In the context of this para-
crine physiology, it has been hypothesized that cytokine
gene–transduced tumor cells can alter the local immuno-
logical environment and thus enhance either antigen pre-
sentation or activation of tumor-specific lymphocytes. 
To date, authors of several studies have attempted to ex-
ploit the ability of cytokine gene–transduced tumor cells
in the immunotherapy of tumors. For instance, Glick and
colleagues8 demonstrated a significant increase in survival
in the mouse glioma model when tumor cells mixed with
IL-2–secreting allogeneic fibroblasts were injected intra-
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Object. Local delivery of cytokines has been shown to have a potent antitumor activity against a wide range of
malignant brain tumors. In this study, the authors examined the efficacy of treating central nervous system (CNS)
tumors by transfecting poorly immunogenic B16/F10 melanoma cells with interleukin (IL)-2, IL-4, or granulocyte-
macrophage–colony stimulating factor (GM-CSF) gene, and using these cells to deliver the cytokine locally at the site
of the CNS tumor. The object was to determine which cytokine would possess the greatest antitumor activity and to
further elucidate its mechanism of action.
Methods. The transfected B16/F10 cells were irradiated to prevent replication and injected intracranially into
C57BL/6 mice (10 mice per group) along with nonirradiated, nontransfected B16/F10 (wild-type) melanoma cells.
Sixty percent of mice treated with IL-2 (p , 0.001 compared with control) and 10% treated with IL-4 (median sur-
vival = 31 days, p , 0.001 compared with control) were long term survivors (. 120 days). The median survival for
animals treated with GM-CSF was 22 days with no long term survivors (p = 0.01 compared with control). Control ani-
mals that received only wild-type cells had a median survival of 18 days (range 15–20 days). Histopathological exam-
ination of brains from animals killed at different times showed minimal infiltration of tumor cells in the IL-2 group,
moderate infiltration of tumor cells in the IL-4 group, and gross tumor invasion and tissue necrosis in the GM-CSF
group. Animals treated with IL-2 showed a strong CD8 T cell–mediated response, whereas IL-4 evoked a prominent
eosinophilic infiltrate in the area of the tumor. 
Conclusions. High levels of locally expressed IL-2 rather than IL-4 or GM-CSF stimulate a strong immunological
cytotoxic antitumor response that leads to significant prolongation of survival in mice challenged with B16/F10 intra-
cranial melanoma tumor cells. Consequently, IL-2 may be a superior candidate for use in paracrine immunotherapy.
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cerebrally. This work has been further corroborated by re-
ports from our own laboratory in which IL-2 was previ-
ously shown to have potent antitumor activity against the
B16/F10 intracranial melanoma model.21 Two other cyto-
kines, IL-4 and GM-CSF, were found to have potential
therapeutic applications. For example, cells engineered to
secrete IL-4 have been shown to cure animals with renal
cell tumors.9 In turn, GM-CSF has been shown to play a
major role in the induction of long-lived systemic antitu-
mor immunity capable of rejecting tumors in animals pre-
viously immunized with a gene-transduced tumor cell.6,12
In this study, our objective was to compare directly the
antitumor efficacy of IL-2, IL-4, and GM-CSF in a single
model and to elucidate each cytokine’s mechanism of
action. By using tumor cell lines transfected with genes
for each of these cytokines, we examined their efficacy in
treating mice with CNS tumors. We then performed
immunohistochemical analysis of animal brains to pro-
vide a better understanding of the nature of the immune
response.
MATERIALS AND METHODS
Tumor Cell Lines and Animals
The B16/F10 melanoma cells (National Cancer Insti-
tute-Division of Cancer Treatment and Diagnosis Tumor
Repository [Frederick, MD]) were cultured in Dulbec-
co's modified Eagle Medium containing 10% fetal calf
serum and penicillin/streptomycin. The B16/F10 cells
were transduced with the murine IL-2, IL-4, and GM-CSF
genes by using the MFG retroviral vector, as previously
described.6 The amount of IL-2, IL-4, or GM-CSF pro-
duced by the transformed tumor cells was measured be-
fore each experiment by a standard enzyme-linked
immunosorbent assay technique (Endogen, Cambridge,
MA). Cultured monolayers were harvested with trypsin
and resuspended in Dulbecco's modified Eagle Medium
before injection. Tumor cells were exposed to 5000 cGy
from a 137-cesium source (Gammacell model 62 irradia-
tor; Nordin International, Inc., Kanata, Ontario, Canada)
discharging 1378 cGy/minute, immediately before injec-
tion to render them incapable of replication. The C57BL/6
female mice (6–12 weeks old) were obtained from Harlan
(Indianapolis, IN). 
Experimental Intracranial Model
Mice were anesthetized with an intraperitoneal injec-
tion of 0.1 ml of a stock solution containing 25 mg/ml
ketamine hydrochloride, 2.5 mg/ml xylazine, and 14.25%
ethyl alcohol diluted 1:3 in 0.9% NaCl. For stereotactic
intracranial injections of tumor cells, the surgical site was
shaved and prepared with 70% ethyl alcohol and prepo-
dyne solution. After a midline incision, a 1-mm right pari-
etal burrhole centered 2 mm posterior to the coronal suture
and 2 mm lateral to the sagittal suture was made. Animals
were then placed in a stereotactic frame and cells were
delivered by a 26-gauge needle to a depth of 3 mm over
a period of 3 minutes. The total volume of injected cells
was 5 µl. The needle was removed, the site was irrigated
with sterile 0.9% NaCl, and the skin was sutured with
4.0 vicryl.
Intracranial Cytokine Studies
The efficacy of local paracrine intracranial immuno-
therapy was tested in three experimental groups (10 mice
in each group). The antitumor activity of irradiated IL-2–,
IL-4–, or GM-CSF–secreting tumor cells was compared
to that in control animals that received coinjections of
wild-type tumor combined with either irradiated wild-type
tumor cells or 0.9% NaCl. All animals were treated with
stereotactic intracranial injections of 100 live nonirradiat-
ed, noncytokine–producing B16/F10 melanoma cells. In-
jection of these cells has been shown to produce a large
tumor at the injection site that is uniformly fatal, with a
median animal survival time between 16 and 18 days.21
Based on our previously published toxicity studies, each
of the animals received 7.5 3 104 IL-2–producing cells
(80 ng/106 cells/24 hours), 2.5 3 106 IL-4–producing cells
(40 ng/106 cells/24 hours), or 105 GM-CSF–producing
cells (60 ng/106 cells/24 hours).22 The results are based on
five independent sets of experiments performed over the
course of this study.
Histological Evaluation 
One set of 10 animals was set aside for the purpose of
histopathological examination. The animals were killed
on Days 1, 4, 9, and 14. The brains were removed, the tis-
sue was fixed in 10% formalin, blocked in paraffin, sec-
tioned in the coronal plane in 10-mm sections, and stained
with hematoxylin and eosin. Immunohistochemical analy-
sis using the peroxidase–antiperoxidase technique was
also used with the following primary antisera: CD3, CD4,
L26, or CD8. A murine lymph node was used as a posi-
tive control.
Statistical Analysis
For all efficacy studies, survival was the primary end-
point. All animals were monitored for any sign of neuro-
toxicity and underwent autopsy, when possible, to confirm
that death was due to intracranial tumor. Survival was
plotted using a Kaplan–Meier survival analysis and statis-
tical significance was determined by the Kruskal–Wallis
nonparametric analysis of variance followed by the non-
parametric analog of the Newman–Keuls' multiple com-
parison test.13
RESULTS
Intracranial Paracrine Immunotherapy With IL-2 Rather
Than IL-4 or GM-CSF Significantly Inhibits Tumor Cell
Proliferation
All of the animals treated in this study were divided into
one of the four groups receiving: IL-2, IL-4, GM-CSF,
and control (Fig. 1 and Table 1). Sixty percent of mice
treated with IL-2 (p , 0.001 compared with control) and
10% treated with IL-4 (median survival 31 days; p ,
0.001 compared with control) were long-term survivors
(.120 days). The median survival for animals treated
with GM-CSF was 22 days (p = 0.01 compared with con-
trol). Control animals that received only wild-type cells
had a median survival of 18 days (range 15–20 days).
Within the experimental group, IL-2 was superior to IL-4
and GM-CSF (Table 2). Histopathological examination of
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brains in animals killed 14 days after injection of tumor
cells showed that the majority of tumor cells were cen-
tered in the region of caudate/putamen, septal nuclei, and
ventricular spaces. Furthermore, the tumor cells were
noncohesive and associated with an inflammatory infil-
trate. The brain surrounding the injection site showed
some reactive changes with a mild leptomeningeal in-
flammatory infiltrate. There was minimal infiltration with
tumor cells in the IL-2 group (, 1 mm), a moderate
amount of tumor infiltration in the IL-4 group (1–2 mm),
and a significant tumor volume in the GM-CSF group (.
2 mm) (Fig. 2).
The Immune Response in Mice Treated With IL-2 is
Composed of CD8 T Cells
To understand the antitumor effects of IL-2 better,
we stained animal brains with different tissue markers.
Whereas all animals treated with IL-2 reacted strongly
with the T-cell marker CD3, none of them showed any
evidence of an L26 B-cell response. Furthermore, when
examined for CD4 or CD8 markers, the brains of the mice
treated with IL-2 stained negatively for CD4 and positive-
ly for CD8 (Fig. 3). These results showed no variation in
the type of immune infiltrate over a course of 2 weeks.
Mice Treated With Intracranial Il-4 Mount an
Eosinophilic Response to Tumor Cells
Although animals treated with IL-4 did not survive as
long as those treated with IL-2, they lived longer than ani-
mals treated with GM-CSF and those in the control group.
Histopathological examination of the brains of animals
treated with IL-4 showed no evidence of infiltration with
CD3, L26, CD4, or CD8 cells (Fig. 3). Nevertheless, these
animals showed a strong eosinophilic infiltrate in the area
of tumor injection that appeared as early as Day 1 after
tumor injection and disappeared by Day 14 following
tumor injection (Fig. 4). 
Tumor Cell Infiltrates of Mice Treated With GM-CSF
Show no Immune Response
Mice treated with GM-CSF had the poorest survival
and greatest tumor burden at death. Examination of the
brains of animals treated with GM-CSF showed a lack of
immune response, with no evidence of staining for CD3,
L26, CD4, CD8, or eosinophils. 
DISCUSSION
The role of the immune system in the response to
tumors of the CNS remains a matter of debate. For many
years, it was believed that the BBB effectively prevented
any interaction between the immune system and the brain
parenchyma. In recent years, however, the results of nu-
merous studies indicate an active although unclear role of
the immune system in the CNS. The breakdown of the
BBB that occurs with both malignant and metastatic brain
tumors clearly causes infiltration of inflammatory cells
within the tumor confines.1,16 Moreover, considerable evi-
dence has accumulated indicating that activated T cells
can pass through an intact BBB and enter the CNS.10,22
The identification of tight connections between the CNS
and the immune system through cervical lymphatics has
further demonstrated that both the afferent and efferent
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Fig. 1. Graph showing survival of mice after intracranial deliv-
ery of cytokine-transduced tumor cells and intracranial tumor chal-
lenge. Animals were treated with a single intracranial injection of
irradiated B16/F10 melanoma cells engineered by gene transfer
to secrete IL-2, IL-4, or GM-CSF. Control animals received intra-
cranial injections of either normal saline or irradiated wild-type
B16/F10 cells (noncytokine producing) (10 animals per group). All
animals were challenged at the same time as their treatment with
intracranial stereotactically coinjected nonirradiated wild-type
B16/F10 melanoma cells. The results represent cumulative data for
five independent sets of experiments. The mice receiving IL-2 and
those treated with IL-4 showed prolongation of survival compared
with controls (p , 0.001 for IL-4, p , 0.001 for IL-2).
TABLE 1
Statistical analysis of experimental data after intracranial 
delivery of cytokine-transduced tumor cells and 
intracranial tumor challenge*
No. & %
Median Survival Long Term p vs.
Cytokine (Days) Survivors Control
IL-2 NA 30, 60% p , 0.001
IL-4 31 5, 10% p , 0.001
GM-CSF 22 0 p = 0.24
control 18 0 NA
* NA = not applicable.
TABLE 2
Comparative statistical analysis of experimental data 
between different cytokine groups
Cytokine p Value
IL-2 vs IL-4 0.01
IL-2 vs GM-CSF , 0.0001
IL-4 vs GM-CSF , 0.0001
arms of the immune system are functional and that pas-
sage of lymphocytes into the CNS can occur via expres-
sion of specific adhesion molecules.5,23 Taken together, the
results of these studies clearly indicate that the immune
system plays an important although not fully understood
role in the body’s natural response to brain tumors.
In our laboratory, we have focused on using melanoma
cells transduced with genes for different cytokines, which
have been irradiated to prevent replication, as vehicles for
delivery of the cytokine locally to the brain tumor. The
B16/F10 melanoma cell line is an attractive tumor model
because it is poorly immunogenic and expresses low lev-
els of MHC Class I and no MHC Class II molecules.6 As
such, the B16/F10 tumor can be recognized by CD8 cyto-
toxic T cells although it cannot directly present tumor
antigens to CD4 cells because this presentation is MHC
Class II restricted. Because cytokines work best in a
paracrine fashion, local to the site of their release, we have
exploited this fact in the delivery of cytokines to brain
tumors. We have previously shown that paracrine IL-2 has
a potent antitumor response against the B16/F10 mel-
anoma model.21 In addition, we have demonstrated syn-
ergy between locally delivered IL-2 and local chemother-
apy.17 Investigators from other laboratories have shown
some degree of efficacy with locally delivered IL-4 as
well as GM-CSF;4,6,9,20 however, a direct comparison of
these different cytokines has hitherto not been described
previously.
In this investigation, we compared the efficacy of IL-2,
IL-4, and GM-CSF in the treatment of B16/F10 melano-
ma both via efficacy studies and by histopathological ex-
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Fig. 2. Photomicrographs of animal brains 2 weeks after in-
jection of tumor cells. A: There was minimal infiltration with tu-
mor cells in the IL-2 group (, 1 mm). B: There was a moderate
amount of tumor infiltration in the IL-4 group (1–2 mm). C:
There was a significant tumor volume in the GM-CSF group (. 2
mm). The tumor cells were centered mostly in the region of cau-
date/putamen, septal nuclei, and ventricular spaces. H & E, origi-
nal magnification 3 20.
Fig. 3. Photomicrographs showing the results of immunohis-
tochemical analysis of animal brains stained for the presence of
the T-cell marker CD8. Animals treated with (A) IL-2, (B) IL-4, or
(C) GM-CSF showed the presence of CD8 cells (arrowheads) only
in the IL-2 treatment group. There was no evidence of CD8 cells
in either the IL-4 or the GM-CSF group. Original magnifica-
tion 3 300.
amination of animal tissue. Through histological and im-
munohistochemical examination of animal brains, we
were able to show significant differences in the action of
the three cytokines. By taking advantage of these differ-
ences and developing strategies that further enhance the
immune response, we hope to develop new immunothera-
peutic approaches for the treatment of CNS tumors.
Interleukin-2 Protects Animals From Intracranial Tumor
Challenge via a CD8 T-Cell Response
Of the three ILs used in this study, IL-2 was clearly
superior to both IL-4 and GM-CSF against B16/F10. Mice
treated with IL-2 not only survived longer, but more than
60% of the IL-2 group were long-term survivors (. 120
days). Examination of the brains of animals treated with
IL-2 showed very little to almost no tumor infiltration at
2 weeks posttumor challenge. In stark contrast, animals
treated with IL-4 or GM-CSF showed progressive increas-
es in tumor volume. When the brains of animals treated
with IL-2 were examined immunohistochemically, sever-
al important findings were noted. First, all of the animals
in the IL-2 group mounted an inflammatory response, as
shown by the presence of polymorphonuclear cells and
lymphocytes. Second, these lymphocytes consisted pri-
marily of T cells rather than B cells. And finally, only the
CD8 T cells were found in the tumor cell infiltrates.
The discovery of CD8 T cells in the infiltrate of tumor
cells treated with IL-2 was of particular interest. It clearly
showed that the immune system, when appropriately stim-
ulated, can mount an immune response against CNS tu-
mors. This is a T-cell–mediated response and not based on
immunological memory as would be expected if B cells
were present. Furthermore, only CD8 T cells, and not
CD4 T cells, appear to play a role in the antitumor re-
sponse. Whether this is because the B16/F10 melanoma
cells express only MHC Class I molecules or there is an
intrinsic defect in normal MHC Class II–restricted antigen
presentation in the CNS is a matter of debate. However,
recent work by Elliott, et al.,7 has implicated a defect in
IL-2 secretion and in the expression of the high affinity
IL-2 receptor in the CD4 T cell subpopulation. This defect
is not amenable to exogenous IL-2 administration and is
likely caused by immunosuppressive substances secreted
by tumors, among them transforming growth factor–b,
IL-10, insulin-like growth factor, and prostaglandin-2.11,15
Taken together, these findings suggest that overcoming
the CD4 anergy while preventing the effects of the im-
munosuppressive substances might enhance not only anti-
gen presentation in the CNS, but also the antitumor activ-
ity of the cytotoxic antitumor lymphocytes.
Interleukin-4 Induces an Eosinphilic Immune Response
That Prolongs the Survival of Mice With CNS Tumors
Although not as effective as IL-2, IL-4 also appears to
play role in inducing some antitumor activity (Table 1).
Examination of the brains of animals treated with IL-4
showed no evidence of polymorphonuclear cells or lym-
phocytes. However, as previously described, there was a
marked eosinophilic infiltrate present throughout the
course of the immune response. For IL-4–transduced tu-
mors, the presence of an eosinophilic infiltrate has been
attributed to the expression of a vascular cell adhesion
molecule on local vascular endothelial cells by IL-4. Vas-
cular cell adhesion molecule appears to be the most im-
portant ligand for the VLA-4 receptor, which is expressed
on circulating eosinophils.18 That eosinophils can play a
direct role in an antitumor response is not well supported
but IL-4 has been shown to confer potent antitumor ef-
fects. For example, Golumbek, et al.,9 showed that admin-
istration of IL-4 can cure animals with renal cell tumors,
and Yu, et al.,24 reported that IL-4 prolongs survival of
mice with glial tumors. In this setting, one can speculate
that the eosinophilic infiltrate induced by IL-4 can medi-
ate the immune response in one of two ways. Either it
serves to promote the direct killing activity of eosinophils
via the basic granular proteins and the peroxidase–halide
generating system or the eosinophils serve as antigen-pre-
senting cells in the CNS. Evidence for the latter comes
from studies by Huang, et al.,12 who showed that the gen-
eration of systemic, although not necessarily CNS, immu-
nity by IL-4 may be due at least in part to the enhanced
presentation of tumor antigens by influxing macrophages
and eosinophils.
No Benefit From GM-CSF in the Treatment of Mice
Challenged With Tumor Induction
Although GM-CSF has been previously shown to be
beneficial in the treatment of systemic cancers,4,6,20 our
results do not support a role for direct administration of
GM-CSF in the CNS. In this study, animals treated with
GM-CSF did not survive longer than control animals.
Histopathologically, brains of animals treated with GM-
CSF showed no evidence of any immune infiltrate, which
would account for the lack of the immune response and
therefore the animals' poor survival. Previous work from
our laboratory suggests that this cytokine is most effective
when administered as a subcutaneous vaccine rather than
directly to the brain.21 This is because of the ability of
GM-CSF to promote the recruitment and differentiation of
professional antigen-presenting cells such as dendritic
cells at the vaccine site.12,19 As such, its application would
be better in the context of an immune vaccine, where the
priming of immune cells with both a foreign antigen and
GM-CSF has been shown to have potentially remarkable
antitumor effects.
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Fig. 4. Photomicrograph of stained sections of animals treated
with IL-4, showing the presence of an eosinophilic infiltrate (ar-
rowhead). H & E, original magnification 3 300.
CONCLUSIONS
To aid in the development of promising new immuno-
therapies targeted at cancer, we have examined the effects
of three important cytokines delivered directly to B16/F10
intracranial melanoma tumors. Although both IL-2 and
IL-4 appear to have antitumor capacities, IL-2 is clearly
superior to IL-4. We have found no role for locally admin-
istered GM-CSF in our study. Consequently, we propose
that further efforts related to the development of cytokine-
based therapies should focus on IL-2, and in particular,
determination of the mechanism by which this cytokine
stimulates a subset of CD8 T cells. The ability to enhance
the intrinsic properties of IL-2 and block the immunosup-
pressive effects of various tumors could offer a powerful
approach in the continually evolving therapies against
both systemic and CNS tumors.
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